MAPT and Alzheimer disease: Furthermore, a recently developed plasma biomarker for imaging, cerebrospinal fluid, or plasma biomarkers of amyloid and tau pathology can be used to assist in the early screening and diagnosis of MCI and AD, as well as the use of cognitive-related scales.